Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Adlai Nortye Ltd. American Depositary Shares (ANL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: ANL (1-star) is a SELL. SELL since 1 days. Simulated Profits (-7.10%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.76% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.93M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta -0.88 | 52 Weeks Range 1.10 - 3.89 | Updated Date 10/12/2025 |
52 Weeks Range 1.10 - 3.89 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1220.88% |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -103.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31814974 | Price to Sales(TTM) 29.86 |
Enterprise Value 31814974 | Price to Sales(TTM) 29.86 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA - | Shares Outstanding 31236934 | Shares Floating 66714945 |
Shares Outstanding 31236934 | Shares Floating 66714945 | ||
Percent Insiders 8.59 | Percent Institutions 0.19 |
Upturn AI SWOT
Adlai Nortye Ltd. American Depositary Shares
Company Overview
History and Background
Adlai Nortye Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative oncology medicines. Founded with a commitment to address unmet medical needs in cancer treatment, the company has focused on developing a pipeline of therapies designed to improve outcomes for cancer patients.
Core Business Areas
- Oncology Drug Development: Discovery and development of novel oncology therapeutics, focusing on areas such as targeted therapies and immuno-oncology.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates in various cancer indications.
- Commercialization: Planning for the commercial launch of approved products, including marketing and sales strategies.
Leadership and Structure
Information not readily available. More information is required to provide an accurate and updated description of the Leadership team and the Organizational structure.
Top Products and Market Share
Key Offerings
- AN2025 (Buparlisib): A PI3K inhibitor being developed for various cancer indications. Market share data and competitor information is not publicly available, but it competes with other PI3K inhibitors in development from companies like Novartis (NOVN).
- AN0025: An EP4 antagonist being developed for cancer immunotherapy. Market share data and competitor information is not publicly available, but it competes with other immuno-oncology therapies from companies like Merck (MRK) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by an aging population, increased cancer incidence, and advancements in cancer treatment. Immunotherapy, targeted therapy, and personalized medicine are key trends.
Positioning
Adlai Nortye Ltd. is positioned as a company focusing on novel oncology therapies, seeking to differentiate itself through innovative drug candidates and strategic partnerships.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth billions of dollars, with continued growth expected. Adlai Nortye Ltd. is positioned to capture a share of this TAM with its pipeline of novel therapies. Accurate estimate requires more information regarding indication types that are being targeted.
Upturn SWOT Analysis
Strengths
- Pipeline of novel oncology drug candidates
- Focus on innovative therapies
- Strategic partnerships
Weaknesses
- Limited commercialization experience
- Dependence on clinical trial success
- High R&D costs
Opportunities
- Expansion into new markets
- Strategic collaborations with larger pharmaceutical companies
- Potential for breakthrough therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- BMY
- NOVN
Competitive Landscape
Adlai Nortye Ltd. faces competition from established pharmaceutical companies with greater resources and commercialization experience. Its competitive advantage lies in its novel drug candidates and focus on specific areas of unmet need.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's development stage.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates require more information
Recent Initiatives: Focus on advancing clinical trials and seeking partnerships to accelerate drug development.
Summary
Adlai Nortye Ltd. is a biopharmaceutical company with a promising pipeline of oncology therapies. Its success depends on navigating the regulatory landscape, securing partnerships, and achieving clinical trial success. As a development-stage company, it faces risks related to funding, competition, and commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | Co- Founder, CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.adlainortye.com |
Full time employees 123 | Website https://www.adlainortye.com | ||
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.